Basic Information
| LncRNA/CircRNA Name | circEPSTI1 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, western blot, Microarray, other |
| Sample | breast cancer tissues and cell lines (HCC38, HCC1806, BT549,MDA-MB-231, MDA-MB-468, MDA-MB-415, MCF-7,T47D, BT474 and Skbr-3) |
| Expression Pattern | up-regulated |
| Function Description | Knockdown of circEPSTI1 inhibits TNBC cell proliferation and induces apoptosis. In vitro and in vivo experiments indicated that circEPSTI1 binds to miR-4753 and miR-6809 as a miRNA sponge to regulate BCL11A expression and affect TNBC proliferation and apoptosis. High levels of circEPSTI1 correlate with reduced survival in TNBC patients. |
| Pubmed ID | 30083277 |
| Year | 2018 |
| Title | circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression |
External Links
| Links for circEPSTI1 | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |